Related Experiment Videos
Preevacuation serum CA 125 in complete hydatidiform mole
S Tangtrakul1, S Srisupandit, L O Chailurkit
1Department of Obstetrics and Gynecology, Faculty of Medicine, Mahidol University, Bangkok, Thailand.
Gynecologic Oncology
|March 1, 1997
Summary
Serum CA 125 levels were elevated in about half of patients with complete hydatidiform mole. However, elevated CA 125 could not predict the development of persistent trophoblastic disease.
Area of Science:
- Gynecology
- Oncology
- Reproductive Medicine
Background:
- Limited studies exist on CA 125 in hydatidiform mole.
- Hydatidiform mole requires monitoring for potential complications.
Purpose of the Study:
- To measure preevacuation serum CA 125 levels in complete hydatidiform mole patients.
- To assess if CA 125 can predict persistent trophoblastic disease.
Main Methods:
- Immunoradiometric measurement of serum CA 125 in 69 complete hydatidiform mole patients.
- Analysis of CA 125 levels in relation to disease progression.
Main Results:
- Mean serum CA 125 level was 63.7 U/ml.
- 53.6% of patients had elevated CA 125 (>35 U/ml).
- No significant difference in CA 125 levels between patients with benign course and those who developed persistent trophoblastic disease.
Conclusions:
- Elevated CA 125 is common in complete hydatidiform mole.
- Serum CA 125 is not a reliable predictor of persistent trophoblastic disease.